-
1
ARIES-HM3 found that aspirin avoidance after de novo HeartMate 3 implantation, with continued vitamin K antagonist anticoagulation, was noninferior for survival free of major nonsurgical hemocompatibility-related adverse events and reduced major bleeding.
-
2
PRAISE HM3 uses deidentified electronic health records from 30 US health systems to assess aspirin-use patterns after LVAD implantation and outcomes among contemporary HeartMate 3 recipients.
-
3
The study examines changes in documented early aspirin use relative to ARIES-HM3 publication in November 2023 and the FDA labeling revision in August 2024.
-
4
Clinical outcome analyses include eligible HeartMate 3 recipients implanted from June 3, 2021, through December 31, 2025, with documented warfarin therapy within 14 days and no major nonsurgical hemocompatibility-related adverse event through the day-14 landmark.
-
5
Early aspirin exposure is defined by recorded administration, dispensing, or an active medication order on postoperative days 2–7. These records identify the initial treatment strategy rather than confirmed long-term adherence.
